Clinical phenotype and cytokine profile of adult IgA vasculitis with joint involvement
Authors:
- 18 January 2022
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (5) , 1483-1491
Abstract
Objective Joint involvement can be observed during the course of adult IgA vasculitis (IgAV). However, clinical picture, prognosis, or pathophysiological data associated with this condition have been overlooked. We aimed to describe the clinical characteristics and outcome of IgAV patients with joint involvement and look to a specific cytokine profile. Methods We analyzed clinical and biological data from a nationwide study that included adult IgAV patients. Presentation and outcomes of patients with or without joint involvement were compared at baseline and during follow-up. Plasma cytokine measurements of IgAV patients included in a prospective study were also analyzed using multiplex assays. Results Among 260 patients, 62% had joint involvement. Among them, rheumatological manifestations included arthralgia (100%) or arthritis (16%), mostly involving the knees and ankles. In multivariate analysis, patients with joint involvement, compared to those without, were younger (p = 0.002; OR 0.87; 95% CI 0.80–0.95) and showed more frequent gastrointestinal tract involvement (p = 0.012; OR = 2.08; 95% CI 1.18–3.67). However, no difference in terms of clinical response, relapse, end-stage renal disease, or death was observed between groups. Among 13 cytokines measured, plasma interleukin (IL)-1β level was higher in patients with joint involvement compared to those without (mean ± SEM IL-1β, 3.5 ± 1.2 vs. 0.47 ± 0.1 pg/ml; p = 0.024) or healthy controls (vs. 1.2 ± 0.5 pg/ml; p = 0.076). Conclusion Joint involvement is frequent in adult IgAV and is associated with more frequent gastrointestinal involvement. Increased plasma IL-1β levels raise the question of targeting this cytokine in patients with chronic and/or refractory joint involvement. Key Points • Joint involvement in adult IgAV is a frequent manifestation. • Joint involvement is associated with more frequent gastrointestinal manifestations. • Interleukin-1β (IL-1β) might orchestrate joint inflammation in adult IgAV. • IL-1β might be a therapeutic target in patients with chronic and/or refractory joint involvement.Keywords
This publication has 41 references indexed in Scilit:
- Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective studyArchives of Disease in Childhood, 2010
- Clinical Manifestations and Outcomes of Henoch-Schönlein Purpura: Comparison between Adults and ChildrenPediatrics & Neonatology, 2009
- The Interleukin 1β Pathway in the Pathogenesis of OsteoarthritisThe Journal of Rheumatology, 2008
- Recurrent Henoch-Schönlein Purpura in ChildrenJCR: Journal of Clinical Rheumatology, 2007
- Early prednisone therapy in Henoch-Schönlein purpura: A randomized, double-blind, placebo-controlled trialThe Journal of Pediatrics, 2006
- Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch–Schönlein purpuraScandinavian Journal of Rheumatology, 2006
- The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantationClinical Transplantation, 2004
- The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritisRheumatology, 2003
- Henoch‐Schönlein purpura in adulthood and childhood. Two different expressions of the same syndromeArthritis & Rheumatism, 1997
- Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis.Journal of Clinical Investigation, 1990